NasdaqGM:NVTR

Stock Analysis Report

Executive Summary

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Risks

  • Nuvectra has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Nuvectra's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-16.4%

NasdaqGM:NVTR

0.8%

US Medical Equipment

1.1%

US Market


1 Year Return

-92.9%

NasdaqGM:NVTR

9.6%

US Medical Equipment

2.1%

US Market

NVTR underperformed the Medical Equipment industry which returned 9.1% over the past year.

NVTR underperformed the Market in United States of America which returned 2% over the past year.


Share holder returns

NVTRIndustryMarket
7 Day-16.4%0.8%1.1%
30 Day-9.8%0.2%3.7%
90 Day-61.1%2.7%2.3%
1 Year-92.9%-92.9%10.5%9.6%4.4%2.1%
3 Year-78.7%-78.7%69.5%64.3%47.0%37.4%
5 Yearn/a132.5%105.9%61.6%43.8%

Price Volatility Vs. Market

How volatile is Nuvectra's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nuvectra undervalued based on future cash flows and its price relative to the stock market?

0.38x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Nuvectra to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Nuvectra to establish if it is available at substantial discount.


Price Based on Earnings

Nuvectra is loss making, we can't compare its value to the US Medical Equipment industry average.

Nuvectra is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Nuvectra, we can't assess if its growth is good value.


Price Based on Value of Assets

Nuvectra is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Nuvectra expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

9.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Nuvectra's revenue is expected to grow by 10.5% yearly, however this is not considered high growth (20% yearly).

Nuvectra is not considered high growth as it is expected to be loss making for the next 1-3 years.

Nuvectra's revenue growth is expected to exceed the United States of America market average.

Unable to compare Nuvectra's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Nuvectra's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Nuvectra will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Nuvectra performed over the past 5 years?

-19.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Nuvectra does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Nuvectra's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Nuvectra's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Nuvectra has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Nuvectra has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Nuvectra improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Nuvectra's financial position?


Financial Position Analysis

Nuvectra is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Nuvectra's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Nuvectra's level of debt (64.2%) compared to net worth is high (greater than 40%).

Unable to establish if Nuvectra's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Nuvectra has sufficient cash runway for 1.4 years based on current free cash flow.

Nuvectra has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 15.1% each year.


Next Steps

Dividend

What is Nuvectra's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Nuvectra's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Nuvectra's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Nuvectra has not reported any payouts.

Unable to verify if Nuvectra's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Nuvectra has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Nuvectra's salary, the management and board of directors tenure and is there insider trading?

1.1yrs

Average management tenure


CEO

Fred Parks (72yo)

0.6yrs

Tenure

US$118,554

Compensation

Dr. Fred B. Parks, Ph.D., has been Chief Executive Officer of Nuvectra Corporation since February 1, 2019 and has been its Interim President since June 27, 2019. Dr. Parks served as the Chief Executive Off ...


Management Age and Tenure

1.1yrs

Average Tenure

44yo

Average Age

The average tenure for the Nuvectra management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.5yrs

Average Tenure

63yo

Average Age

The tenure for the Nuvectra board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$31,44207 Jun 19
Joseph Hanchin
EntityIndividual
Shares7,900
Max PriceUS$3.98
BuyUS$36,12523 May 19
Benjamin Tranchina
EntityIndividual
Role
Chief Technology Officer
Chief Technology Officer
Shares8,500
Max PriceUS$4.25
BuyUS$102,34007 May 19
Kenneth Hawari
EntityIndividual
Role
Member of the Board of Directors
Director
Shares17,000
Max PriceUS$6.02
BuyUS$122,40006 May 19
David Johnson
EntityIndividual
Role
Member of the Board of Directors
Director
Shares20,000
Max PriceUS$6.12
BuyUS$87,36006 May 19
Anthony Bihl
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares14,000
Max PriceUS$6.24
SellUS$29,08816 Nov 18
Joseph Hanchin
EntityIndividual
Shares1,600
Max PriceUS$18.18

Ownership Breakdown


Management Team

  • Fred Parks (72yo)

    Interim President

    • Tenure: 0.6yrs
    • Compensation: US$118.55k
  • Daryl Kipke

    President of NeuroNexus

    • Tenure: 0yrs
  • Melissa Beare (44yo)

    Executive VP

    • Tenure: 4.7yrs
  • Benjamin Tranchina

    Chief Technology Officer

    • Tenure: 1.1yrs
  • Jennifer Kosharek (37yo)

    Interim CFO

    • Tenure: 0.3yrs
  • Bonnie Schmidt

    Executive Director of Human Resources

    • Tenure: 4.7yrs
  • Bernie Bosley

    Executive Director of Regulatory & Clinical Affairs

    • Tenure: 0yrs

Board Members

  • Chris Chavez (63yo)

    Independent Director

    • Tenure: 0.6yrs
  • Dave Johnson (63yo)

    Director

    • Tenure: 3.5yrs
    • Compensation: US$131.05k
  • Jon Tremmel (73yo)

    Director

    • Tenure: 3.5yrs
    • Compensation: US$116.05k
  • Ken Hawari (60yo)

    Director

    • Tenure: 3.5yrs
    • Compensation: US$131.05k
  • Jane Song (56yo)

    Independent Director

    • Tenure: 0.5yrs
  • Fred Parks (72yo)

    Interim President

    • Tenure: 0.6yrs
    • Compensation: US$118.55k
  • Tony Bihl (63yo)

    Chairman of the Board

    • Tenure: 0.5yrs
    • Compensation: US$136.05k
  • Tom Zelibor (64yo)

    Director

    • Tenure: 3.5yrs
    • Compensation: US$123.55k

Company Information

Nuvectra Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nuvectra Corporation
  • Ticker: NVTR
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$26.470m
  • Shares outstanding: 17.89m
  • Website: https://www.nuvectramed.com

Number of Employees


Location

  • Nuvectra Corporation
  • 5830 Granite Parkway
  • Suite 1100
  • Plano
  • Texas
  • 75024
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NVTRNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMar 2016
NV6DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2016

Biography

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 00:37
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.